Business Update Neutral

2026-11-06 16:30

Concall Schedule Concall Date: November 13, 2026 Concall Time: 16:00 Hrs IST

Business Update Neutral

2026-11-06 16:29

Concall Schedule Concall Date: November 13, 2026 Concall Time: 16:00 Hrs IST

Ownership Neutral

2026-11-04 15:34

- Promoter V.C. Nannapaneni created a pledge of 8,50,000 equity shares (0.47% of total share capital) of Natco Pharma Limited. - The pledge was created on October 9, 2026, in favor of Bajaj Financial Securities Limited. - The reason for encumbrance is for the purpose of subscribing to the Rights Issue of the Company.

Ownership Neutral

2026-10-30 10:44

- Natco Pharma Ltd has disclosed share acquisitions by promoters and members of the promoter group through a Rights Issue allotment. - Key allottees include Venkaiah Chowdary Nannapaneni (5,86,666 shares), Neelima Sita Nannapaneni (2,55,387 shares), Rajeev Nannapaneni (58,666 shares), and Time Cap Pharma Labs Private Limited (9,33,333 shares). - The date of allotment/acquisition of shares is 26/10/2026.

Governance Positive

2026-10-29 17:23

- Board meeting scheduled on Friday, November 13, 2026. - To consider Unaudited Financial Results for the quarter and half-year ended September 30, 2026. - To consider declaration of second interim dividend for FY 2026-27. - Trading window remains closed until November 15, 2026.

Routine Neutral

2026-10-29 17:18

- Natco Pharma Limited has informed the stock exchanges regarding newspaper publications of the basis of allotment for its Rights Issue. - The notice was published on 29th October, 2026, in Financial Express, Jana Satta, and Surya newspapers.

Ownership Positive

2026-10-23 21:09

- Natco Pharma Limited's Fund-Raising Committee approved the allotment of 1,70,58,082 Equity Shares via Rights Issue on October 23, 2026. - Issue Price: ₹750 per Equity Share (face value ₹2, premium ₹748). - Paid-up equity share capital increased from ₹35,82,19,740 (17,91,09,870 shares) to ₹39,23,35,904 (19,61,67,952 shares).

Ownership Positive

2026-10-23 21:09

- Natco Pharma's Fund-Raising Committee approved the allotment of 1,70,58,082 equity shares through its Rights Issue on October 23, 2026. - The shares were allotted at a price of ₹750 per share (including a ₹748 premium). - Paid-up equity share capital increased from ₹35.82 crore to ₹39.23 crore.

Business Update Positive

2026-10-23 21:07

- Natco Pharma announced the allotment of 1,70,58,082 Equity Shares at ₹750 per share (including a premium of ₹748) pursuant to its Rights Issue. - The paid-up equity share capital of the company increased from ₹35.82 crores to ₹39.23 crores. - The allotment was approved by the Fund Raising Committee on October 23, 2026.

Routine Neutral

2026-10-22 13:27

- Natco Pharma Limited announced the closure of the issue period of its Rights Issue on October 22, 2026. - The Rights Issue opened on October 12, 2026. - The issue involves equity shares of face value ₹2 each at a price of ₹750 each, aggregating up to ₹12,794 million.

Business Update Neutral

2026-10-22 13:23

- Natco Pharma Limited has informed about the closure of the Issue period of its Rights Issue on October 22, 2026. - The Rights Issue offered equity shares of face value Rs. 2/- each at a price of Rs. 750/- per share. - The total aggregating amount of the issue is up to Rs. 12,794 millions. - The issue period opened on October 12, 2026, and closed on October 22, 2026.

Business Update Positive

2026-10-19 14:25

- Natco Pharma announced the launch of Carboplatin Injection (generic version of Paraplatin) in the U.S. market through its subsidiary, in collaboration with Teyro Labs. - The product launch aims to address a critical drug shortage in the U.S. - Carboplatin Injection had estimated U.S. sales of USD 27.8 million for the 12 months ending June 2026.

Business Update Positive

2026-10-19 14:20

- Natco Pharma announced the launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market through its U.S. subsidiary, in collaboration with Teyro Labs. - The product launch aims to address a critical shortage of Carboplatin Injection in the U.S. market. - Carboplatin Injection had estimated U.S. sales of USD 27.8 million for the 12 months ending June 2026.

Ownership Neutral

2026-10-13 10:29

- Promoter V.C. Nannapaneni created a pledge of 8,50,000 equity shares (0.47% of total share capital) of Natco Pharma Limited in favor of Bajaj Financial Securities Limited on 09-10-2026.

Governance Positive

2026-09-30 17:44

- Natco Pharma Limited held its 43rd Annual General Meeting (AGM) on September 30, 2026. - All five resolutions, including adoption of financial statements, confirmation of three interim dividends aggregating to Rs. 5 per share as final dividend, re-appointment of Sri P.S.R.K. Prasad, ratification of cost auditors' remuneration, and approval for raising funds up to Rs. 2,000 crores, were passed with the requisite majority.

Governance Neutral

2026-09-30 12:46

- Natco Pharma Limited held its 43rd Annual General Meeting (AGM) on September 30, 2026, through video conference. - Shareholders considered the adoption of audited financial statements for FY 2025-26 and confirmed three interim dividends aggregating to ₹5.00 per share. - Approved the re-appointment of Sri P.S.R.K. Prasad as Director and ratified the remuneration of Cost Auditors. - Approved raising of funds up to ₹2,000 crores through the issuance of securities.

Routine Neutral

2026-09-28 20:56

- Natco Pharma Limited has informed the stock exchanges about the outcome of the Fund Raising Committee meeting approving the Letter of Offer for its upcoming Rights Issue. - The Rights Issue involves offering up to 17,058,082 fully paid-up equity shares of face value ₹2 each at an issue price of ₹750 per share, aggregating up to ₹12,794 million. - The issue ratio is set at 2 Rights Equity Shares for every 21 fully paid-up equity shares held on the record date of October 1, 2026. - The Issue opens on October 12, 2026, and closes on October 22, 2026, with on-market renunciation ending on October 16, 2026.

Ownership Neutral

2026-09-28 20:55

- Natco Pharma Ltd has announced the outcome of the Fund Raising Committee meeting approving the Letter of Offer for its upcoming Rights Issue. - The company is offering up to 17,058,082 fully paid-up equity shares of face value ₹2 each at an issue price of ₹750 per share, aggregating up to ₹12,794 million. - The rights entitlement ratio is set at 2 equity shares for every 21 fully paid-up equity shares held on the record date of October 1, 2026. - The issue opens on October 12, 2026, and closes on October 22, 2026.

Business Update Positive

2026-09-28 15:01

- Natco Pharma increased its investment in eGenesis, Inc. to US$ 16.70 million from the previously disclosed US$ 14.00 million. - The investment is made through wholly owned subsidiaries: US$ 13.70 million by NATCO Pharma (Canada) Inc. and US$ 3 million by NATCO Pharma USA LLC via convertible promissory notes. - Combined with a previous investment of US$ 8.00 million in 2024, Natco's total investment in eGenesis will reach US$ 24.70 million. - The acquisition is expected to be completed by October 31, 2026. - eGenesis focuses on genome engineering-based approaches for transplantable organs to address global organ shortages.

Business Update Positive

2026-09-28 14:57

Natco Pharma increased its investment in eGenesis, Inc. from US$ 14.00 million to US$ 16.70 million through its wholly owned subsidiaries (NATCO Pharma (Canada) Inc. and NATCO Pharma USA LLC). - Including a prior investment of US$ 8.00 million in 2024, Natco's total investment in eGenesis will reach US$ 24.70 million. - The investment is made via convertible promissory notes with an 8% annual compounded interest rate. - eGenesis is a US-based biotechnology company pioneering genome engineering for transplantable porcine organs to address organ shortages. - The indicative completion time for the acquisition is October 31, 2026.

Routine Neutral

2026-09-25 11:26

- Natco Pharma Ltd has fixed October 1, 2026 as the Record Date for its upcoming Rights Issue of equity shares. - The record date will determine the shareholders eligible to receive Rights Entitlements.

Ownership Neutral

2026-09-25 11:24

- Natco Pharma Limited has fixed October 1, 2026, as the record date for its upcoming Rights Issue. - The record date will determine the eligible shareholders entitled to receive Rights Entitlements.

Financials Neutral

2026-09-25 11:23

- Natco Pharma announced a rights issue of up to 1,70,58,082 equity shares aggregating to ₹1,279.36 crores. - Rights issue price is set at ₹750 per share (including a premium of ₹748). - Rights entitlement ratio is 2 Rights Equity Shares for every 21 fully paid-up Equity Shares held on the record date. - Record date for the rights issue is October 1, 2026. - Rights issue opens on October 12, 2026, and closes on October 22, 2026.

Routine Neutral

2026-09-25 11:21

- Natco Pharma announced a rights issue of up to 1,70,58,082 equity shares aggregating to ₹1,279.36 crores. - Rights issue price is fixed at ₹750 per share (including a premium of ₹748). - Rights entitlement ratio is set at 2 equity shares for every 21 fully paid-up equity shares held on the record date. - Record date for the rights issue is October 1, 2026. - Rights issue opens on October 12, 2026, and closes on October 22, 2026.

Financials Positive

2026-09-25 11:19

- Natco Pharma announced a rights issue of up to 1,70,58,082 equity shares aggregating to ₹1,279.36 crores. - Rights issue price is fixed at ₹750 per share (including a premium of ₹748). - Rights entitlement ratio is set at 2:21 (2 equity shares for every 21 equity shares held). - Record date for the rights issue is October 1, 2026. - Rights issue opens on October 12, 2026, and closes on October 22, 2026.

Financials Positive

2026-09-25 11:18

- Natco Pharma approved a rights issue of up to 1,70,58,082 equity shares aggregating to ₹1,279.36 crores. - Rights issue price is set at ₹750 per share (including a ₹748 premium). - Entitlement ratio is 2 rights equity shares for every 21 fully paid-up equity shares held on the record date. - Record date for the rights issue is October 1, 2026. - Rights issue opens on October 12, 2026, and closes on October 22, 2026.

Governance Positive

2026-09-22 18:00

- Board meeting scheduled for September 25, 2026, to finalize terms for a Rights Issue of up to ₹1,300 crores. - The meeting will determine the Rights Issue price, entitlement ratio, record date, and timing. - Trading window for designated persons will be closed from September 23, 2026.

Business Update Positive

2026-09-21 22:56

- Natco Pharma Limited received in-principle approval from NSE and BSE on September 21, 2026, for its Rights Issue of fully paid-up equity shares.

Business Update Positive

2026-09-21 22:47

- Natco Pharma Limited received in-principle approval from National Stock Exchange of India Limited and BSE Limited on September 21, 2026, for its Rights Issue of fully paid-up equity shares.

Ownership Positive

2026-09-09 17:54

- Natco Pharma Limited proposes to undertake a Rights Issue of its Equity Shares, subject to applicable laws and regulatory approvals. - The company has filed a Draft Letter of Offer in connection with the proposed Rights Issue. - The proposed Rights Issue aggregates up to ₹13,000 Million (₹1300 Cr) on a rights basis.

Ownership Positive

2026-09-09 17:53

- Natco Pharma Limited proposes to undertake a Rights Issue of its Equity Shares. - The company intends to raise up to ₹13,000 Crores (assuming full subscription) through this issue. - A Draft Letter of Offer in connection with the proposed Rights Issue has been filed.

Business Update Positive

2026-09-09 11:55

- Natco Pharma's Board of Directors met on September 9, 2026. - Approved the issuance of fully paid-up equity shares via a Rights Issue for an amount not exceeding ₹1,300 crore. - Constituted a Fund-Raising Committee for the Rights Issue. - Provided an update on the Scheme of Arrangement (Demerger), stating that the Rights Issue will necessitate changes to the Scheme.

Business Update Positive

2026-09-09 11:48

- Board approved a Rights Issue of fully paid-up equity shares of face value ₹2 for an amount not exceeding ₹1,300 crore. - A Fund-Raising Committee was constituted for the Rights Issue. - The Rights Issue will necessitate consequential changes to the ongoing Scheme of Arrangement (Demerger) to maintain the share swap ratio.

Routine Neutral

2026-09-04 20:37

- This is Natco Pharma Limited's Business Responsibility & Sustainability Report for the financial year April 1, 2025 to March 31, 2026. - The report, prepared on a Standalone basis, details the company's ESG performance, policies, and compliance with NGRBC principles and various international standards.

Governance Neutral

2026-09-04 19:11

- Board meeting scheduled for September 9, 2026 - To consider a proposal for fundraising by way of equity shares or other securities.

Business Update Neutral

2026-09-02 19:18

- Investor Meet Schedule - Meeting Date: 7th September 2026 - Meeting Time: 10:00 AM to 1:00 PM - Organized by: Antique Stock Broking - Type: In-person and group - Location: Hyderabad - No Unpublished Price Sensitive Information (UPSI) will be discussed.

Business Update Neutral

2026-09-02 19:11

- Investor Meet Schedule - Meet Date: 7th September 2026 - Meet Time: 10:00 AM to 1:00 PM - Organiser: Antique Stock Broking - Type: In-person and group - Location: Hyderabad

Ownership Neutral

2026-08-26 14:48

- Promoter Smt. Durga Devi Nannapaneni of Natco Pharma Limited gifted 50,000 equity shares to her Niece, Smt. G. Kalajyothi, on August 24, 2026. This reduced her shareholding from 1.98% to 1.95%.

Business Update Positive

2026-08-25 12:23

- NATCO Pharma Limited is investing an additional US$ 14 million in eGenesis, Inc. via convertible promissory notes. - This brings NATCO's total investment in eGenesis to US$ 22 million. - eGenesis is a biotechnology company focused on genome engineering for organ transplantation to address critical unmet medical needs.

Business Update Positive

2026-08-25 12:20

- NATCO Pharma Limited is investing an additional US$ 14 million in eGenesis, Inc., a biotechnology company. - This brings NATCO's total investment in eGenesis to US$ 22 million. - The investment is made through convertible promissory notes to fund new-age therapeutic programmes addressing critical unmet medical needs.

Business Update Neutral

2026-08-24 21:46

- Investor Meet Schedule - Mumbai Meeting Date & Time: Thursday, 27th August 2026, 9:00 AM - 6:00 PM - Hong Kong Meeting Date & Time: Thursday, 27th August 2026 (9:00 AM - 5:00 PM) and Friday, 28th August 2026 (9:00 AM - 1:00 PM) - Meetings organized by Nuvama Wealth Management Limited and ICICI Securities Limited. - Latest investor presentation is available on the company website. - No Unpublished Price Sensitive Information (UPSI) will be discussed.

Business Update Neutral

2026-08-24 20:26

- Investor Meetings Scheduled - Mumbai Meeting: Thursday, 27th August 2026, 9:00 AM - 6:00 PM, with Nuvama Wealth Management & ICICI Securities. - Hong Kong Meeting: Thursday, 27th August 2026, 9:00 AM - 5:00 PM and Friday, 28th August 2026, 9:00 AM - 1:00 PM, with Nuvama Wealth Management & ICICI Securities. - No Unpublished Price Sensitive Information (UPSI) will be discussed.

Business Update Negative

2026-08-21 17:29

CRITICAL RED FLAG DETECTED

- NATCO Pharma announced the conclusion of a US FDA inspection at its Visakhapatnam Finished Dosage Formulations (FDF) Unit on August 21, 2026. - The company received a Form 483 with 4 observations, which it believes are procedural and will address.

Business Update Negative

2026-08-21 17:26

CRITICAL RED FLAG DETECTED

- US FDA inspection concluded at Natco Pharma's Visakhapatnam Finished Dosage Formulations (FDF) Unit from August 17-21, 2026. - Company received Form 483 with 4 observations, which it believes are procedural and will be addressed within stipulated timelines.

Business Update Neutral

2026-08-19 19:18

- Investor Meeting Schedule - Meeting Dates: 24th August 2026 to 26th August 2026 - Meeting Time: 9:30 AM to 6:00 PM - Organized by: Nuvama Wealth Management Limited and ICICI Securities Limited - Location: Singapore

Business Update Neutral

2026-08-19 19:15

- Investor Meet Schedule - Date: Monday, 24th August 2026 to Wednesday, 26th August 2026 - Time: 9:30 AM to 6:00 PM - Type: In-person group meeting in Singapore - Organized by: Nuvama Wealth Management Limited and ICICI Securities Limited

Business Update Positive

2026-08-19 09:05

- NATCO Pharma Limited released its Investor Presentation for August 2026, highlighting strong operational delivery. - Global revenues for FY26 stood at INR 43,759 Million ($495 Million). - The company achieved double-digit CAGR growth from FY17 to FY26: Revenue (8%), EBITDA (10%), and PAT (11%). - Recent milestones (2025-2026) include launching Risdiplam and Semaglutide vials, and acquiring an additional 13.25% stake in Adcock Ingram Holdings Limited.

Business Update Positive

2026-08-19 09:02

- Investor Presentation dated August 2026, outlining the company's performance and strategic initiatives. - Achieved strong operational growth from FY17 to FY26 with Revenue CAGR of 8%, EBITDA CAGR of 10%, and PAT CAGR of 11%. - Reported FY26 Global revenues of INR 43,759 Million. - Recent updates include the launch of Semaglutide vials and acquiring an additional 13.25% stake in Adcock Ingram Holdings Limited.

Business Update Positive

2026-08-18 12:42

- Q1 FY27 consolidated revenue declined to ₹794.4 Cr from ₹1,390.6 Cr YoY, mainly due to lower Lenalidomide revenue, partially offset by double-digit growth in base business. - Q1 FY27 EBITDA stood at ₹245.7 Cr with a margin of 30.9%. - Full-year PAT guidance is maintained around ₹750 Cr, and gross sales guidance between ₹3,300 Cr to ₹3,400 Cr. - The company acquired an additional 13.25% stake in Adcock Ingram in July 2026, increasing total holding to 49%, which significantly contributed to Q1 profits. - Domestic business volumes are expected to increase by about 25% this year, driven by semaglutide and oncology segments. - Brazil business revenue grew 180% to ₹178 Cr, with continued growth anticipated. - Plans to raise ₹2,000 Cr via QIP/rights issue for potential M&A opportunities (one in India, one outside), short-term loans, and annual organic CAPEX of ₹250-300 Cr. - Carfilzomib launch is on track for Calendar '27; targeting 8-10 ANDAs and 2-3 First-to-File applications annually, with two new product launches for the U.S. market planned for FY28. - The demerger of the Crop Health Science business, which generated ₹40 Cr in Q1 and aims to break even for the year, may be delayed to March due to fundraising activities.

Business Update Positive

2026-08-18 12:40

- Q1 FY27 consolidated revenue decline attributed to lower Lenalidomide, partially offset by double-digit growth in the base business. - Management maintains annual PAT guidance of approx. ₹750 crores, clarifying Q1 impact due to seasonality and specific product cycles. - Strategic acquisition of an additional 13.25% stake in Adcock Ingram, increasing total holding to 49%, aimed at strengthening presence in the South African market. - Strong growth observed in domestic formulation business and Brazil (180% growth), driven by the oncology pipeline and new launches. - The company plans to raise ₹2,000 crores for M&A opportunities, evaluating both domestic and international prospects. - Key launches like Carfilzomib are on track for calendar '27; management is optimistic about innovation assets like eGenesis and is targeting 1-2 First-To-File launches this year.

Business Update Neutral

2026-08-16 20:03

- Investor Meet Schedule - Date: August 19-21, 2026 - Time: 9:00 AM to 5:00 PM - Details: In-person Group meeting in Mumbai/Maharashtra, organized by Nuvama Wealth Management and ICICI Securities. No UPSI will be discussed.

Business Update Neutral

2026-08-16 19:57

- Concall Schedule - Concall Date: 19th to 21st August 2026 - Concall Time: 9:00 AM to 5:00 PM - Type: In-person group meeting - Organized by: Nuvama Wealth Management Limited and ICICI Securities Limited - Location: Mumbai, Maharashtra - No Unpublished Price Sensitive Information (UPSI) will be discussed.

Business Update Neutral

2026-08-14 19:05

- Audio weblink for Natco Pharma's Q1 FY26-27 earnings conference call held on August 14, 2026, has been provided. The recording is available on the company's website.

Business Update Neutral

2026-08-14 18:56

- Audio weblink for the Q1 FY26-27 earnings conference call held on August 14, 2026, is provided. The link is available on the company's website.

Financials Negative

2026-08-14 17:44

- Q1 FY27 Consolidated Revenue ₹7,944Mn vs ₹13,906Mn (▼42.9% YoY) - EBITDA ₹2,457Mn vs ₹6,327Mn (▼61.2% YoY) - PAT ₹2,065Mn vs ₹4,803Mn (▼57.0% YoY) - EBITDA Margin 30.9% vs 45.5% (▼1460bps)

Financials Negative

2026-08-14 17:41

- Q1 FY27 Consolidated Revenue ₹794.4Cr vs Q1 FY26 ₹1,390.6Cr (▼42.87% YoY) - EBITDA ₹245.7Cr vs Q1 FY26 ₹632.7Cr (▼61.18% YoY) - PAT ₹206.5Cr vs Q1 FY26 ₹480.3Cr (▼57.00% YoY) - EBITDA Margin 30.9% vs 45.5% (▼1460bps)

Routine Neutral

2026-08-14 14:23

New Filing detected. See link for details.

Routine Neutral

2026-08-14 14:19

New Filing detected. See link for details.

Routine Neutral

2026-08-14 14:17

New Filing detected. See link for details.

Routine Neutral

2026-08-14 14:16

New Filing detected. See link for details.

Business Update Neutral

2026-08-11 18:02

- Concall Schedule - Concall Date: Friday, August 14, 2026 - Concall Time: 17:30 PM IST

Governance Neutral

2026-08-11 17:56

- Board Meeting to be held on August 14, 2026. - Purpose: To consider and evaluate proposals for raising funds through issuance of equity shares or other securities (e.g., public issue, preferential issue, rights issue, private placement, QIP).

Business Update Neutral

2026-08-11 17:48

- Concall Schedule - Concall Date: August 14, 2026 - Concall Time: 17:30 PM IST - To discuss Q1FY27 Un-audited Financial Results for the quarter ended June 30, 2026.

Financials Positive

2026-08-06 16:52

- Board meeting on August 14, 2026, to consider unaudited financial results for the quarter ended June 30, 2026. - Board will also consider interim dividend, if any, for the financial year 2026-27. - Trading window for dealing in company securities will be closed from August 7, 2026, to August 16, 2026.

Business Update Positive

2026-07-18 16:51

- Natco Pharma Limited received tentative U.S. FDA approval for Olaparib Tablets (100mg & 150mg). - The drug, bioequivalent to AstraZeneca's Lynparza®, had estimated U.S. sales of ~USD 1.4 billion in 12 months ending Mar'26. - Natco will manufacture, and Alembic Pharma will distribute the product in the U.S.

Business Update Positive

2026-07-18 16:40

- NATCO Pharma received U.S. FDA tentative approval for Olaparib 100mg and 150mg tablets. - The drug, bioequivalent to Lynparza®, had estimated U.S. sales of ~USD 1.4 billion for 12 months ending Mar'26.

Routine Neutral

2026-07-14 11:55

New Filing detected. See link for details.

Routine Neutral

2026-07-14 11:52

New Filing detected. See link for details.

Routine Neutral

2026-07-14 10:08

New Filing detected. See link for details.

Governance Neutral

2026-07-14 09:58

CRITICAL RED FLAG DETECTED

- Natco Pharma received an order from Asst. Commissioner (ST) imposing a tax demand, interest, and penalty totaling ~₹59.87 lakhs for under-reporting Reverse Charge Mechanism (RCM) in GSTR 3B during FY20-24. The company states there is no material impact on its operations and is evaluating the matter.

Business Update Positive

2026-07-08 12:06

- Board approved an investment of ₹1400 Crores in Natco Pharma South Africa Proprietary Limited, a wholly-owned subsidiary of the company. - Board approved acquiring 19,618,825 shares in Adcock Ingram Holdings Proprietary Limited for ₹1069 crores (ZAR 1.8 billion), increasing its stake from 35.75% to 49%. - The objective is to expand geographic footprint, growth, and profitability in South Africa and the continent of Africa. - Adcock Ingram reported a topline of US$ 423 million and EBITDA of ~US$ 59 million for the 9 months ending March 31, 2026.

Business Update Positive

2026-07-08 12:05

- Natco Pharma's Board approved an investment of ₹1400 Crores in Natco Pharma South Africa Proprietary Limited, its wholly-owned subsidiary. - The Board also approved increasing its stake in Adcock Ingram Holdings Proprietary Limited from 35.75% to 49% for ₹1069 Crores. - This strategic investment aims to expand the geographic footprint and increase profitability, with completion expected by July 2026.

Governance Positive

2026-07-06 17:49

- Natco Pharma Limited designated Mr. Gnanadeva Chalapathy Gudipati as Senior VP - Analytical R&D and Mr. Madhava Rao Karicherla as VP - Formulation R&D, Pharma Division, Kothur Unit, effective July 6, 2026, strengthening the management team.

Governance Neutral

2026-07-06 17:41

- Mr. Gnanadeva Chalapathy Gudipati designated as Senior Vice President - Analytical Research & Development. - Mr. Madhava Rao Karicherla designated as Vice President – Formulation Research & Development, Pharma Division, Kothur Unit. - The designations are effective from 6th July, 2026.

Governance Neutral

2026-06-30 16:21

- Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division - Kothur of Natco Pharma Limited, has superannuated. - His cessation is effective from the closure of business hours on 30th June, 2026.

Routine Neutral

2026-06-30 16:17

- Trading window for dealing in company securities will close from July 1, 2026. - It will remain closed until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. - The date of the board meeting for results will be intimated in due course.

Governance Neutral

2026-06-30 16:13

- Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division, superannuated effective from the closure of business hours on June 30, 2026.

Routine Neutral

2026-06-30 16:10

- Trading window for dealing in the company's securities will be closed from July 1, 2026. - It will reopen 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. - The Board Meeting date for results will be announced later.

Business Update Negative

2026-06-04 15:02

CRITICAL RED FLAG DETECTED

- FY27 Consolidated Revenue guidance: INR 3,400-3,500 crores. - FY27 Consolidated PAT guidance: INR 700-750 crores, a significant contraction from FY26. - The company acknowledges a 'muted' FY27 with a dip in earnings due to competitive pressures, particularly from Revlimid. - Growth drivers include diversification into Brazil (projected to reach INR 450-500 crores in FY27) and Canada (10-15% growth), and the Adcock Ingram acquisition in South Africa. - Semaglutide vial launch in India is targeted for INR 75-100 crores annualized revenue. - Company holds INR 2,400 crores net cash and is actively seeking M&A opportunities, primarily outside India. - R&D spend is expected to be 7-9% of revenue for FY27, focusing on complex and first-to-file products. - Management expects earnings to compound 15-25% annually from FY28 onwards, driven by new exclusivities and diversified portfolio. - Aiming to reduce earnings volatility by having base revenue contribute 70% of profit, and special products 25-30% within 5 years.

Business Update Negative

2026-06-04 14:56

CRITICAL RED FLAG DETECTED

- The company reported a decline in consolidated total revenue for FY26 to ₹4,375.9 crores (from ₹4,784 crores in FY25) and net profit to ₹1,418.5 crores (from ₹1,883.4 crores in FY25), mainly due to the impact of Revlimid and increased freight expenses. - Management guided for a further significant decline in FY27, with expected revenue of ₹3,400-3,500 crores and PAT of ₹700-750 crores, a substantial reduction from FY26 actuals. - The tax rate for FY27-FY28 is expected to be around 25%, and R&D expenses are projected at 7-9% of earnings for the next year. - Beyond FY27, the company anticipates 15-25% compounded annual growth, driven by new exclusivities and product launches in Brazil and Canada, aiming for more stable, diversified earnings. - Key initiatives include geographical diversification through acquisitions (Brazil, Canada, South Africa, India) with ~₹2,400 crores net cash for M&A, and the semaglutide launch targeting ₹75-100 crores annualized. - The Crop Health Sciences business grew to ₹140 crores in FY26 (from ₹60 crores in FY25) and is in the process of demerger.

Business Update Positive

2026-06-03 11:16

- NATCO Pharma Limited and its alliance partner Lupin Limited received approval from the U.S. FDA for NATCO's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2ml (0.5 mg/ml) Single-Dose Vials. - The injection is bioequivalent to the reference listed drug Halaven® Injection of Eisai, Inc. - It is indicated for the treatment of adults with metastatic breast cancer and unresectable or metastatic liposarcoma. - The Reference Listed Drug (RLD) Halaven® had estimated annual sales of USD 43.7 million in the U.S.

Business Update Positive

2026-06-03 11:15

- NATCO Pharma Limited and Lupin Limited received approval from the U.S. FDA for Eribulin Mesylate Injection, 1 mg/2ml (0.5 mg/ml) Single-Dose Vials. - This injection is bioequivalent to Halaven® Injection and is indicated for metastatic breast cancer and liposarcoma. - The reference listed drug had estimated annual sales of USD 43.7 million in the U.S. (IQVIA MAT April 2026).

Business Update Neutral

2026-05-30 12:21

Natco Pharma Limited submitted the transcript of its earnings conference call for Q4 FY25-26, which was held on May 29, 2026. The transcript is enclosed and also available on the company's website.

Business Update Neutral

2026-05-30 12:19

Natco Pharma Limited informed the exchanges about the enclosure of the transcript of its earnings conference call for Q4 FY25-26, which was held on May 29, 2026. The transcript is also available on the company's website.

Financials Negative

2026-05-29 15:32

Consolidated Revenue ₹8,169 Mn vs ₹12,873 Mn (▼36.5% YoY), EBITDA ₹2,054 Mn vs ₹6,144 Mn (▼66.6% YoY), PAT ₹2,690 Mn vs ₹4,060 Mn (▼33.7% YoY). EBITDA Margin 25.1% vs 47.7% (▼2260bps).

Financials Negative

2026-05-29 14:30

Consolidated Revenue ₹739.1Cr vs ₹1,221.0Cr (▼39.5% YoY), EBITDA ₹127.6Cr vs ₹548.1Cr (▼76.7% YoY), PAT ₹269.0Cr vs ₹406.0Cr (▼33.7% YoY), with EBITDA Margin 15.62% vs 44.89% (▼2927bps); the Q4 PAT includes a one-time deferred tax asset benefit of ₹115.0Cr.

Financials Negative

2026-05-29 14:22

NATCO Pharma Limited reported consolidated Q4 FY26 results with Total Income of ₹816.9 Cr compared to ₹1,287.3 Cr in Q4 FY25 (▼36.6% YoY). EBITDA was ₹127.6 Cr vs ₹548.1 Cr (▼76.7% YoY). Net Profit (PAT) stood at ₹269.0 Cr vs ₹406.0 Cr (▼33.7% YoY). EBITDA Margin significantly contracted to 15.6% from 42.6% (▼2700bps). Q4 FY26 PAT includes a one-time deferred tax asset benefit of ₹115.0 Cr.

Financials Negative

2026-05-29 14:19

Consolidated Revenue from operations for Q4 FY26 was ₹739.1Cr vs ₹1,221.0Cr (▼39.5% YoY), EBITDA was ₹127.6Cr vs ₹548.1Cr (▼76.7% YoY), and PAT was ₹269.0Cr vs ₹406.0Cr (▼33.7% YoY). EBITDA Margin contracted from 44.9% to 17.3% (▼2760bps). The net profit for the quarter includes a one-time benefit of ₹115Cr from moving to a new tax regime and re-measuring deferred tax assets.

Governance Neutral

2026-05-26 16:23

Natco Pharma Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as per Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report confirms overall compliance with applicable statutory provisions. It noted that some related party transactions lacked prior audit committee approval but were subsequently ratified by the Audit Committee and Board of Directors. The report also stated that no actions were taken against the company by SEBI or stock exchanges during the review period.

Business Update Neutral

2026-05-21 12:29

Natco Pharma Limited will host an earnings call for investors and analysts on Friday, May 29, 2026, at 4:30 PM IST. The call, hosted by 360 ONE Capital Market Private Limited, will discuss the company's Audited Financial Results for the quarter and year ended March 31, 2026. Key management, including the Vice-chairman and CEO, CFO, and EVP, Crop Health Sciences, will participate.

Business Update Negative

2026-05-14 16:19

CRITICAL RED FLAG DETECTED

Natco Pharma Limited received a demand notice on May 12, 2026, from the National Pharmaceutical Pricing Authority. The notice directs the company to deposit ₹4,92,25,923/-, including overcharge, penalty, and interest, for allegedly overcharging on two drugs between April 2023 and November 2023. The company stated there is no material impact on its financial, operational, or other activities.

Routine Neutral

2026-04-09 10:52

Natco Pharma Limited submitted the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026, confirming securities received for dematerialization were processed and depository records updated.

Routine Neutral

2026-03-31 13:58

Natco Pharma Ltd. announced the closure of the trading window for Directors, Designated Persons, and connected persons from April 1, 2026, until 48 hours after the declaration of financial results for the quarter and year ending March 31, 2026. The date of the Board Meeting will be intimated in due course.

Governance Positive

2026-03-25 15:44

Natco Pharma announced the results of its postal ballot held from February 12 to March 24, 2026. All resolutions were passed with requisite majority, confirming the re-appointment of Sri V. C. Nannapaneni as Chairman & MD, Sri Rajeev Nannapaneni as Vice Chairman & CEO, and two other directors with effect from April 1, 2026.

Governance Positive

2026-03-24 17:16

Natco Pharma's board approved demerging its Agrochemicals Business into Natco Crop Health Sciences Ltd, effective October 1, 2026. Shareholders get 1 share of the new entity for every 1 held. Also approved: forming a Nigerian subsidiary and liquidating an Australian one.

Business Update Positive

2026-03-20 09:32

Natco Pharma launched Semaglutide Generic Injection multi-dose vials in India on March 20, 2026, at an affordable price starting from INR 1,290 per month. It's the first to offer this GLP-1 therapy in vial form, making it significantly cheaper than innovator brands.

Business Update Neutral

2026-03-06 10:25

Natco Pharma Limited announced participation in the Investec Promoter and Founder Conference 2026 on March 9, 2026, in Mumbai. No Unpublished Price Sensitive Information will be discussed during the meeting.

Business Update Positive

2026-03-03 10:31

NATCO Pharma Limited announced on March 3, 2026, the launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market, in partnership with Breckenridge Pharmaceutical, Inc. The generic drug targets multiple myeloma and AIDS-related Kaposi sarcoma. Pomalidomide Capsules had estimated sales of USD 3.2 billion in the U.S. for 12 months ending Sep '25.

Business Update Positive

2026-02-25 10:02

Natco Pharma confirmed receiving CDSCO approval for Semaglutide in India on Feb 14, 2026. The company plans to launch the product with marketing partners, including Eris Lifesciences Ltd, in March 2026. They stated the partnership has no material financial impact.

Routine Neutral

2026-02-24 16:55

New Filing detected. See link for details.

NATCOPHARM

Natco Pharma Ltd

Price Chart

Filing History

Unlock Full History